Simple Summary Effector immune system cells have the ability to kill tumor cells. However,
as a cancer (such as leukemia) develops, it inhibits and evades the effector immune …

The immune microenvironment is a critical driver and regulator of leukemic progression and
hematological disease. Recent investigations have demonstrated that multiple immune …

Cancer immunotherapies are receiving increasing approval in the clinic, but still only a
fraction of patients benefit long-term. Understanding the most important mechanisms of …

Myeloid-derived suppressor cells (MDSCs) are pathologically activated neutrophils and
monocytes that negatively regulate the immune response to cancer and chronic infections …

Tumor-promoting inflammation and escape from immune-mediated tumor destruction have
been recognized as hallmarks of cancer, and myeloid cells are key players in these …

Myeloid cells are the most abundant nucleated haematopoietic cells in the human body and
are a collection of distinct cell populations with many diverse functions. The three groups of …

Simple Summary The tumor is a complex system that is composed of tumor cells,
themselves surrounded by many other different cell types. Among these cells, myeloid cells …

Functional interplay between acute myeloid leukemia (AML) cells and the bone marrow
microenvironment is a distinctive characteristic of this hematological cancer. Indeed, a large …

Simple Summary Despite remarkable progress in the outcome of childhood acute myeloid
leukemia (AML), risk of relapse and refractory diseases remains high. Treatment of the …

Myeloid differentiation is often disturbed in cancer, leading to reduced frequencies of
immunostimulatory dendritic cells and an over-representation of immunosuppressive …